Association between intensive intravenous iron treatment and angina pectoris in hemodialysis patients [2]

Clinical Nephrology

Volumn 66, Issue 4, 2006, Pages 312-313

  Malindretos, P ^a   Sioulis, A ^a   Avgeriou, E ^a   Michalaki, A ^a   Roma, V ^a   Grekas, D M ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMORBIDITY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; IRON BLOOD LEVEL; LETTER;

EID: 33749613477     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66312     Document Type: Letter

References (4)

1. Fishbane S, Maesaka J, Mittal S. Is there material hazard to treatment with intravenous iron? Nephrol Dial Transplant. 1999; 14: 2595-2598.
2. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease. Update 2000. 2001; Am J Kidney Dis 37 (Suppl 1): 182-238.
3. Rooyakkers T, Stroes E, Kooistra M, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. 2002; Eur J Clin Invest 32 (Suppl 1): 9-16.
4. Silveberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-417.